Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Positive save search
Kiora Pharmaceuticals Reports First Quarter Results; Positive Clinical Data Driving Significant Progress Advancing Pipeline of Eye Disease Treatments
Published: 2023-05-09 (Crawled : 16:00) - biospace.com/
KPRX | $0.504 -13.03% -14.98% 290K
|
Manufacturing
|
| O: -0.79%
H: 7.57%
C: 0.8%
disease positive pipeline pharmaceuticals eye
Seres Therapeutics Publishes Positive SER-287 Phase 1b Ulcerative Colitis Study Results in Journal Gastroenterology
Published: 2021-01-06 (Crawled : 15:00) - biospace.com/
MCRB | $0.7295 -4.01% -4.18% 5.8M
|
Health Technology
|
| O: -1.56%
H: 11.53%
C: 7.04%
positive results phase 1b phase 2b ulcerative colitis
Finch Therapeutics Announces Positive Topline Results from PRISM-EXT Phase 2 Trial of CP101 for Prevention of Recurrent C. difficile Infection
Published: 2021-11-09 (Crawled : 22:00) - globenewswire.com
FNCH | $2.305 -17.35% -20.99% 120K
|
Professional, Scientific, and T...
|
| O: 15.94%
H: 0.19%
C: -7.44%
phase 2 positive results topline trial injection infections
Finch Therapeutics Presents Positive Data from PRISM3 Clinical Trial of CP101 for Recurrent C. difficile at American College of Gastroenterology Annual Scientific Meeting
Published: 2021-10-25 (Crawled : 14:00) - biospace.com/
FNCH | $2.305 -17.35% -20.99% 120K
|
Professional, Scientific, and T...
|
| O: -0.9%
H: 7.94%
C: 7.86%
positive trial
Palisade Bio and Newsoara Announce Positive Topline Efficacy Results from Phase 2 Study of LB1148 Demonstrating Accelerated Return of Bowel Function After Gastrointestinal Surgery
Published: 2021-07-29 (Crawled : 20:00) - biospace.com/
PALI | $6.39 7.94% 7.36% 460K
|
Manufacturing
|
| O: 12.23%
H: 3.95%
C: -19.09%
phase 2 test positive results topline gastrointestinal
Palisade Bio Announces Positive Preclinical Data of Lead Program PALI-2108 at the 2024 Crohn’s & Colitis Congress
Published: 2024-01-29 (Crawled : 13:00) - globenewswire.com
PALI | $6.39 7.94% 7.36% 460K
|
Manufacturing
|
| O: 125.0%
H: 27.35%
C: -17.95%
pali-2108 congress positive preclinical program
High Tide Reports Third Quarter 2021 Financial Results Featuring a 99% Increase in Revenue and Sixth Consecutive Quarter of Positive Adjusted EBITDA
Published: 2021-09-14 (Crawled : 20:00) - prnewswire.com
HITI | $2.015 -6.28% -6.7% 910K
|
Manufacturing
|
| O: -0.96%
H: 0.14%
C: -4.7%
ACB | $7.2 14.65% 12.78% 5.7M
|
Process Industries
|
| O: -0.31%
H: 3.55%
C: 3.09%
TLRY | $1.83 -0.54% -0.55% 18M
|
Process Industries
|
| O: 0.17%
H: 3.61%
C: 2.3%
financial results positive results
Aurora Repurchases ~US$9.0 Million Principal Amount of Convertible Notes; Continues Progress Towards Positive Free Cash Flow with less than ~US$39 Million of Notes Outstanding
Published: 2023-09-08 (Crawled : 22:00) - prnewswire.com
ACB | $7.2 14.65% 12.78% 5.7M
|
Process Industries
| Email alert
Add to watchlist
free positive flow
TFF Pharmaceuticals Announces Positive Preclinical Results with Two Biodefense Countermeasures for the United States Army Medical Research Institute of Infectious Diseases (USAMRIID)
Published: 2021-02-19 (Crawled : 17:00) - biospace.com/
TFFP | $3.04 2.36% 2.3% 13K
|
Health Technology
|
| O: 1.29%
H: 1.01%
C: -2.37%
disease defense infectious disease positive results research preclinical pre-clinical
Augmenta Bioworks and TFF Pharmaceuticals Announce Positive In Vitro Data Demonstrating Binding and Neutralization of the SARS-CoV-2 Delta Variant by Lead Anti-COVID-19 Antibody, AUG-3387
Published: 2021-07-29 (Crawled : 12:15) - globenewswire.com
TFFP | $3.04 2.36% 2.3% 13K
|
Health Technology
|
| O: 2.89%
H: 0.0%
C: -1.57%
covid anti-covid positive antibody sars-cov-2 in vitro
TFF Pharmaceuticals and Augmenta Bioworks Publish Positive In Vivo Data Showing Dry Powder Formulation of COVID-19 Antibody, AUG-3387, Neutralizes SARS-CoV-2 Infection and Reduces Viral Load
Published: 2021-10-14 (Crawled : 13:00) - biospace.com/
TFFP | $3.04 2.36% 2.3% 13K
|
Health Technology
|
| O: 2.12%
H: 6.63%
C: 2.86%
covid positive antibody injection sars-cov-2 infections
TFF Pharmaceuticals Announces Positive Initial Data from Ongoing Phase 2 Trials of TFF VORI and TFF TAC
Published: 2023-12-19 (Crawled : 11:00) - globenewswire.com
TFFP | $3.04 2.36% 2.3% 13K
|
Health Technology
|
| O: 17.75%
H: 0.0%
C: -22.4%
positive ongoing pharmaceuticals trials
TFF Pharmaceuticals Announces Additional Positive Data from the Tacrolimus Inhalation Powder (TFF TAC) Phase 2 Trial Following Oral Presentation at the ISHLT 44th Annual Late Breaking Clinical Science Abstract Sessions
Published: 2024-04-15 (Crawled : 11:00) - globenewswire.com
TFFP | $3.04 2.36% 2.3% 13K
|
Health Technology
|
| O: 0.25%
H: 1.26%
C: -11.56%
tacrolimus presentation positive sessions pharmaceuticals trial
BiomX Announces Positive Results from Part 1 of the Phase 1b/2a Study Evaluating BX004 for Treatment of Chronic Pulmonary Infections in Patients with Cystic Fibrosis
Published: 2023-02-22 (Crawled : 14:00) - globenewswire.com
PHGE | $0.3274 -5.51% 3.82% 130K
|
Health Technology
|
| O: -5.36%
H: 3.69%
C: 3.69%
bx004 treatment fibrosis infections positive study cystic fibrosis
BiomX Announces Positive Topline Results from Part 2 of the Phase 1b/2a Trial Evaluating BX004 for Treatment of Chronic Pulmonary Infections in Patients with Cystic Fibrosis
Published: 2023-11-29 (Crawled : 12:00) - globenewswire.com
PHGE | $0.3274 -5.51% 3.82% 130K
|
Health Technology
|
| O: -30.36%
H: 14.21%
C: -23.08%
bx004 positive treatment fibrosis topline infections trial results
BiomX to Host Virtual Key Opinion Leader (KOL) Event to Review the Positive Results from Part 2 of Phase 1b/2a Trial of BX004 in Cystic Fibrosis Patients with Chronic Pseudomonas aeruginosa Infections on December 4, 2023
Published: 2023-11-30 (Crawled : 00:00) - biospace.com/
PHGE | $0.3274 -5.51% 3.82% 130K
|
Health Technology
|
| O: 5.4%
H: 3.26%
C: -18.09%
bx004 review positive fibrosis infections trial results
Maxim Group: Society Pass (Nasdaq: SOPA) Despite Challenging Global Macro Environment, Reiterates Positive Outlook on SOPA Based on Strong Revenue Generation and Compelling Valuation
Published: 2022-11-17 (Crawled : 13:20) - globenewswire.com
SOPA | $0.1513 8.07% 7.47% 2.7M
|
|
| O: -1.89%
H: 8.33%
C: 5.13%
global positive
Maxim: Society Pass (Nasdaq: SOPA) – Compelling Valuation; Positive on Organic Growth & M&A; Raises Revenue Targets for 2023 and 2024
Published: 2023-08-14 (Crawled : 13:00) - globenewswire.com
SOPA | $0.1513 8.07% 7.47% 2.7M
|
|
| O: -1.03%
H: 3.09%
C: 1.19%
organic positive growth
Maxim: Society Pass (Nasdaq: SOPA) - 1Q22 Results and Outlook; Positive on Opportunities in the SE Asia E-commerce Market
Published: 2022-05-19 (Crawled : 18:00) - globenewswire.com
SOPA | $0.1513 8.07% 7.47% 2.7M
|
|
| O: -2.79%
H: 8.62%
C: 4.6%
results market positive
Society Pass Inc (Nasdaq: SOPA): Maxim Issues 3Q 2023 Equity Research Update; Maintains Positive Outlook on Organic Growth & M&A
Published: 2023-11-22 (Crawled : 13:00) - globenewswire.com
SOPA | $0.1513 8.07% 7.47% 2.7M
|
|
| O: 9.18%
H: 0.0%
C: -6.81%
organic positive research growth
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.